Side-by-side comparison of AI visibility scores, market position, and capabilities
Falls Church stealth defense systems (NYSE: NOC) ~$41B revenue; B-21 Raider stealth bomber (operational 2024), Sentinel ICBM, $1.4B IBCS air defense contracts for US Army and Poland competing with Lockheed Martin.
Northrop Grumman Corporation is a Falls Church, Virginia-based global aerospace and defense technology company — publicly traded on the New York Stock Exchange (NYSE: NOC) as an S&P 500 Industrials component — designing, developing, producing, and maintaining advanced defense systems including stealth combat aircraft, space systems, ground-based strategic nuclear weapons, battle management systems, and unmanned systems through approximately 95,000 employees worldwide. In fiscal year 2024, Northrop Grumman reported revenue of approximately $41 billion, with defense spending tailwinds from NATO alliance expansion, Indo-Pacific military modernization, and US Air Force strategic deterrence modernization. Northrop Grumman secured $1.4 billion in contracts to advance the Integrated Battle Command System (IBCS) — a next-generation air and missile defense battle management system for the US Army and Poland, connecting disparate sensors (radar, sonar, space-based sensors) and effectors (Patriot batteries, short-range air defense missiles) through a unified software-defined kill chain. CEO Kathy Warden — the first female CEO of a major US defense contractor — leads Northrop's strategy of focusing on the highest-technology defense programs where integration complexity creates durable sole-source competitive positions. The B-21 Raider stealth strategic bomber (the first new US strategic bomber in 35 years, beginning operational deliveries in 2024) is Northrop's defining program — a next-generation nuclear-capable stealth aircraft intended to replace the B-2 Spirit and eventually the B-1 Lancer through the late 2030s.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.